Leila Mahdavi

Leila Mahdavi

Auto-generated profile, based on publicly available information

Leila Mahdavi

Division of Pediatric Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2022 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
YLYiman Liu
Yiman Liu
QLQinglan Li
Qinglan Li
FAFatemeh Alikarami
Fatemeh Alikarami
DBDeclan R. Barrett
Declan R. Barrett
LMLeila Mahdavi
Leila Mahdavi
LWLiling Wan
Liling Wan
The chromatin reader eleven–nineteen leukemia (ENL) has been identified as a critical dependency in acute myeloid leukemia (AML), but its therapeutic potential remains unclear. We describe a potent and orally bioavailable small-molecule inhibitor of ENL, TDI-11055, which displaces ENL from chromatin by blocking its YEATS domain interaction with acylated histones. Cell lines and primary patient samples carrying MLL rearrangements or NPM1 mutations are responsive to TDI-11055. A CRISPR-Cas9–mediated mutagenesis screen uncovers an ENL mutation that confers resistance to TDI-11055, validating the compound's on-target activity. TDI-11055 treatment rapidly decreases chromatin occupancy of ENL-associated complexes and impairs transcription elongation, leading to suppression of key oncogenic gene expression programs and induction of differentiation. In vivo treatment with TDI-11055 blocks disease progression in cell line– and patient-derived xenograft models of MLL-rearranged and NPM1-mutated AML. Our results establish ENL displacement from chromatin as a promising epigenetic therapy for molecularly defined AML subsets and support the clinical translation of this approach. Significance: AML is a poor-prognosis disease for which new therapeutic approaches are desperately needed. We developed an orally bioavailable inhibitor of ENL, demonstrated its potent efficacy in MLL-rearranged and NPM1-mutated AML, and determined its mechanisms of action. These biological and chemical insights will facilitate both basic research and clinical translation. This article is highlighted in the In This Issue feature, p. 2483

8 May 2025 in Blood
Verified
Journal Article
Open access
FAFatemeh Alikarami
Fatemeh Alikarami
HXhongbo xie
hongbo xie
SRSimone S. Riedel
Simone S. Riedel
HGHaley T. Goodrow
Haley T. Goodrow
DBDeclan R. Barrett
Declan R. Barrett
KBKathrin Maria Bernt
Kathrin Maria Bernt
Stemness-associated cell states are linked to chemotherapy resistance in acute myeloid leukemia (AML). We uncovered a direct mechanistic link between expression of the stem cell transcription factor GATA2 and drug resistance. The GATA-binding protein 2 (GATA2) plays a central role in blood stem cell generation and maintenance. We find substantial intrapatient and interpatient variability in GATA2 expression across samples from patients with AML. GATA2 expression varies by molecular subtype and has been linked to outcome. In a murine model, KMT2A-MLL3–driven AML originating from a stem cell or immature progenitor cell population has higher Gata2 expression and is more resistant to the standard AML chemotherapy agent doxorubicin. Deletion of Gata2 resulted in a more robust induction of p53 after exposure to doxorubicin. Chromatin immunoprecipitation sequencing, RNA sequencing, and functional studies revealed that GATA2 regulates the expression of RASSF4, a modulator of the p53 inhibitor MDM2 (mouse double minute 2). GATA2 and RASSF4 are anticorrelated in human cell lines and in bulk and single-cell expression data sets from patients with AML. Knockdown of Rassf4 in Gata2-low cells resulted in doxorubicin or nutlin-3 resistance. Conversely, overexpression of Rassf4 results in sensitization of cells expressing high levels of Gata2. Finally, doxorubicin and nutlin-3 are synergistic in Gata2-high murine AML and in samples from patients with AML. We discovered a previously unappreciated role for GATA2 in dampening p53-mediated apoptosis via transcriptional regulation of RASSF4, a modulator of MDM2. This role for GATA2 directly links the expression of a stemness-associated transcription factor to chemotherapy resistance.

29 September 2025 in Experimental Hematology
Verified
Journal Article
Open access
LMLeila Mahdavi
Leila Mahdavi
FAFatemeh Alikarami
Fatemeh Alikarami
HGHaley Goodrow
Haley Goodrow
ALAlexandra Lenard
Alexandra Lenard
SRSimone S. Riedel
Simone S. Riedel
KBKathrin Maria Bernt
Kathrin Maria Bernt
Inhibitors of the menin-KMT2A interaction are promising agents for the treatment of KMT2A-rearranged leukemias. We evaluated menin inhibition in patient-derived xenografts of KMT2A-rearranged leukemias with high-risk features. Three acute myeloid leukemias with high-risk fusion partners (mixed-lineage leukemia-10 [MLLT10] and mixed-lineage leukemia-4 [MLLT4]) and two infant acute lymphocytic leukemia (ALL) samples were sensitive to menin inhibition. We also evaluated serial samples from two patients with multiply relapsed ALL. We found that highly pretreated KMT2A::AFF1 ALL samples were much less sensitive compared with cells obtained earlier in the same patients' disease course. Because none of the patients had been treated with a menin inhibitor, resistance in these highly pretreated samples was acquired in the absence of menin-inhibitor exposure. Transcriptomic analysis documented sustained on-target efficacy toward the canonical targets of the menin inhibitor in resistant cells. Targeted genomic analysis documented the emergence of multiple comutations, including RAS pathway and TP53 mutations, although neither was sufficient to induce menin-inhibitor resistance in vitro. Downregulation of KMT3D may account for resistance in one patient; inactivation of KMT2C/D has been reported to result in menin-inhibitor resistance, and KMT2C-edited cells from this patient were selected for in menin-inhibitor-containing growth conditions. Future studies will need to clarify more broadly which genomic/epigenomic alterations drive upfront resistance. Regardless of mechanism, our data support using menin inhibitors upfront or in early lines of therapy before substantial genomic or epigenomic evolution has occurred.

4 April 2023
Verified
Other
Open access
YLYiman Liu
Yiman Liu
QLQinglan Li
Qinglan Li
FAFatemeh Alikarami
Fatemeh Alikarami
DBDeclan R. Barrett
Declan R. Barrett
LMLeila Mahdavi
Leila Mahdavi
LWLiling Wan
Liling Wan
Supplementary Data from Small-Molecule Inhibition of the Acyl-Lysine Reader ENL as a Strategy against Acute Myeloid Leukemia

4 April 2023
Verified
Other
Open access
YLYiman Liu
Yiman Liu
QLQinglan Li
Qinglan Li
FAFatemeh Alikarami
Fatemeh Alikarami
DBDeclan R. Barrett
Declan R. Barrett
LMLeila Mahdavi
Leila Mahdavi
LWLiling Wan
Liling Wan
Supplementary Data from Small-Molecule Inhibition of the Acyl-Lysine Reader ENL as a Strategy against Acute Myeloid Leukemia

4 April 2023
Verified
Other
Open access
YLYiman Liu
Yiman Liu
QLQinglan Li
Qinglan Li
FAFatemeh Alikarami
Fatemeh Alikarami
DBDeclan R. Barrett
Declan R. Barrett
LMLeila Mahdavi
Leila Mahdavi
LWLiling Wan
Liling Wan
Supplementary Data from Small-Molecule Inhibition of the Acyl-Lysine Reader ENL as a Strategy against Acute Myeloid Leukemia